104 related articles for article (PubMed ID: 17224890)
1. Impact of chronic kidney disease and diabetes on percutaneous coronary intervention outcomes.
Lepor NE
Rev Cardiovasc Med; 2006; 7 Suppl 4():S38-48. PubMed ID: 17224890
[TBL] [Abstract][Full Text] [Related]
2. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.
Mehilli J; Kastrati A; Schühlen H; Dibra A; Dotzer F; von Beckerath N; Bollwein H; Pache J; Dirschinger J; Berger PP; Schömig A;
Circulation; 2004 Dec; 110(24):3627-35. PubMed ID: 15531766
[TBL] [Abstract][Full Text] [Related]
3. Long term efficacy of abciximab bolus-only compared to abciximab bolus and infusion after transradial coronary stenting.
Bagur R; Bertrand OF; Rodés-Cabau J; Larose E; Rinfret S; Nguyen CM; Noel B; Larochellière RD; Poirier P; Costerousse O; Roy L
Catheter Cardiovasc Interv; 2009 Dec; 74(7):1010-6. PubMed ID: 19753635
[TBL] [Abstract][Full Text] [Related]
4. Treatment of multilesion coronary artery disease with simultaneous drug-eluting and bare-metal stent implantation: clinical follow up and angiographic mid-term results.
Mirabella F; Francaviglia B; Capodanno D; Di Salvo ME; Galassi AR; Ussia GP; Capranzano P; Tamburino C
J Invasive Cardiol; 2009 Apr; 21(4):145-50. PubMed ID: 19342750
[TBL] [Abstract][Full Text] [Related]
5. Antiplatelet therapy in the era of percutaneous coronary intervention with drug-eluting balloons.
Bonaventura K; Sonntag S; Kleber FX
EuroIntervention; 2011 May; 7 Suppl K():K106-11. PubMed ID: 22027718
[TBL] [Abstract][Full Text] [Related]
6. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
[TBL] [Abstract][Full Text] [Related]
7. Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation.
Tentzeris I; Jarai R; Farhan S; Brozovic I; Smetana P; Geppert A; Wojta J; Siller-Matula J; Huber K
Thromb Haemost; 2010 Dec; 104(6):1211-8. PubMed ID: 20941464
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrel.
Morel O; El Ghannudi S; Jesel L; Radulescu B; Meyer N; Wiesel ML; Caillard S; Campia U; Moulin B; Gachet C; Ohlmann P
J Am Coll Cardiol; 2011 Jan; 57(4):399-408. PubMed ID: 21251579
[TBL] [Abstract][Full Text] [Related]
9. Why diabetics are at risk in percutaneous coronary intervention and the appropriate management of diabetics in interventional cardiology.
Reginelli JP; Bhatt DL
J Invasive Cardiol; 2002 Dec; 14 Suppl E():2E-10E; quiz 11E. PubMed ID: 12668857
[TBL] [Abstract][Full Text] [Related]
10. Impact of final activated clotting time after transradial coronary stenting with maximal antiplatelet therapy.
Bertrand OF; Rodés-Cabau J; Rinfret S; Larose E; Bagur R; Proulx G; Gleeton O; Costerousse O; De Larochellière R; Roy L
Am J Cardiol; 2009 Nov; 104(9):1235-40. PubMed ID: 19840568
[TBL] [Abstract][Full Text] [Related]
11. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Kastrati A; Mehilli J; Schühlen H; Dirschinger J; Dotzer F; ten Berg JM; Neumann FJ; Bollwein H; Volmer C; Gawaz M; Berger PB; Schömig A;
N Engl J Med; 2004 Jan; 350(3):232-8. PubMed ID: 14724302
[TBL] [Abstract][Full Text] [Related]
12. Improving outcomes with antiplatelet therapies in percutaneous coronary intervention and stenting.
Hobson A; Curzen N
Thromb Haemost; 2009 Jan; 101(1):23-30. PubMed ID: 19132185
[No Abstract] [Full Text] [Related]
13. Impact of chronic kidney disease on long-term clinical outcomes after percutaneous coronary intervention with drug-eluting or bare-metal stents.
Kersting S; Grumann T; Hummel J; Hauschke D; Bode C; Hehrlein C
Crit Pathw Cardiol; 2012 Sep; 11(3):152-9. PubMed ID: 22825536
[TBL] [Abstract][Full Text] [Related]
14. Abciximab offers greater benefits to insulin-dependent diabetic patients undergoing coronary stent implantation.
López-Mínguez JR; Nogales JM; González R; Palanco C; Doncel J; Vaello A; Giménez F; Morales A; Alonso R; Merchán A
Cardiovasc Revasc Med; 2007; 8(3):175-82. PubMed ID: 17765647
[TBL] [Abstract][Full Text] [Related]
15. Advances in percutaneous coronary intervention in patients with chronic kidney disease.
Coats WC; Dellsperger KC
Adv Perit Dial; 2010; 26():42-6. PubMed ID: 21348378
[TBL] [Abstract][Full Text] [Related]
16. Comparison of higher clopidogrel loading and maintenance dose to standard dose on platelet function and outcomes after percutaneous coronary intervention using drug-eluting stents.
Abuzahra M; Pillai M; Caldera A; Hartley WB; Gonzalez R; Bobek J; Dokainish H; Lakkis N
Am J Cardiol; 2008 Aug; 102(4):401-3. PubMed ID: 18678295
[TBL] [Abstract][Full Text] [Related]
17. Pre-procedural C-reactive protein levels and clinical outcomes after percutaneous coronary interventions with and without abciximab: pooled analysis of four ISAR trials.
Iijima R; Byrne RA; Ndrepepa G; Braun S; Mehilli J; Berger PB; Schömig A; Kastrati A
Heart; 2009 Feb; 95(2):107-12. PubMed ID: 18801777
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcomes after coronary bare-metal-stent and drug-eluting-stent implantations: a 'real-world' comparison among patients with diabetes with diffuse small vessel coronary artery disease.
Koh AS; Chia S; Choi LM; Sim LL; Chua TS; Koh TH; Tan JW
Coron Artery Dis; 2011 Mar; 22(1):96-9. PubMed ID: 21164343
[TBL] [Abstract][Full Text] [Related]
19. One-year clinical outcomes in patients with chronic renal failure treated by percutaneous coronary intervention with drug-eluting stent.
Barthelemy O; Helft G; Silvain J; Bellemain-Appaix A; Beygui F; Choussat R; Berman E; Collet JP; Montalescot G; Metzger JP; Le Feuvre C
Arch Cardiovasc Dis; 2011 Dec; 104(12):604-10. PubMed ID: 22152512
[TBL] [Abstract][Full Text] [Related]
20. Multivessel drug-eluting stenting and impact of diabetes mellitus--a report from the EVENT registry.
Novack V; Tsyvine D; Cohen DJ; Pencina M; Dubin J; Dehghani H; Kleiman NS; Cutlip DE
Catheter Cardiovasc Interv; 2009 Jun; 73(7):874-80. PubMed ID: 19180665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
